EA202190103A1 - Трициклические соединения - Google Patents

Трициклические соединения

Info

Publication number
EA202190103A1
EA202190103A1 EA202190103A EA202190103A EA202190103A1 EA 202190103 A1 EA202190103 A1 EA 202190103A1 EA 202190103 A EA202190103 A EA 202190103A EA 202190103 A EA202190103 A EA 202190103A EA 202190103 A1 EA202190103 A1 EA 202190103A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bet
inhibitors
tricyclic
connections
methods
Prior art date
Application number
EA202190103A
Other languages
English (en)
Inventor
Хайцюань Фан
Минмин Чэнь
Гуйцюнь Ян
Юэлэй Ду
Яньпин ВАН
Тун У
Цинлун Ли
Лэй Чжан
Шаоцзин Ху
Original Assignee
Джакобио Фармасьютикалс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джакобио Фармасьютикалс Ко., Лтд. filed Critical Джакобио Фармасьютикалс Ко., Лтд.
Publication of EA202190103A1 publication Critical patent/EA202190103A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Описаны трициклические соединения в качестве ингибиторов бромодомена и экстра-концевых (BET) ингибиторов, которые показаны на формуле I, их синтез и их применение для лечения заболеваний. Более конкретно, описаны конденсированные производные гетероцикла, применяемые в качестве ингибиторов BET, способы получения таких соединений и способы лечения заболеваний и состояний, где ингибирование одного или нескольких бромодоменов BET оказывает пользу.
EA202190103A 2018-06-25 2019-04-26 Трициклические соединения EA202190103A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018092542 2018-06-25
PCT/CN2019/084601 WO2020001152A1 (en) 2018-06-25 2019-04-26 Tricyclic compounds

Publications (1)

Publication Number Publication Date
EA202190103A1 true EA202190103A1 (ru) 2021-03-29

Family

ID=68986044

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190103A EA202190103A1 (ru) 2018-06-25 2019-04-26 Трициклические соединения

Country Status (15)

Country Link
US (2) US20210179617A1 (ru)
EP (1) EP3814352A4 (ru)
JP (1) JP7168245B2 (ru)
KR (1) KR102600391B1 (ru)
CN (2) CN115109061A (ru)
AU (2) AU2019295983B2 (ru)
BR (1) BR112020026337A2 (ru)
CA (1) CA3104927C (ru)
EA (1) EA202190103A1 (ru)
MX (1) MX2020014111A (ru)
PH (1) PH12020552210A1 (ru)
SG (1) SG11202012819YA (ru)
TW (1) TWI705965B (ru)
WO (1) WO2020001152A1 (ru)
ZA (1) ZA202100237B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115109061A (zh) * 2018-06-25 2022-09-27 北京加科思新药研发有限公司 三环化合物
AU2022211285A1 (en) * 2021-01-22 2023-08-17 Jingrui Biopharma Co., Ltd. Tricyclic compounds as anticancer agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
AU2014249192B2 (en) * 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
CN106029663B (zh) * 2013-12-24 2018-06-01 百时美施贵宝公司 作为抗癌剂的新颖三环化合物
ES2815683T3 (es) * 2015-05-11 2021-03-30 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
US9725449B2 (en) * 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10174024B2 (en) * 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
EP3406612B1 (en) * 2016-01-20 2021-07-21 Ningbo Wenda Pharma Technology Ltd. Carboline derivative serving as bromodomain inhibitor
WO2017133681A1 (zh) 2016-02-05 2017-08-10 正大天晴药业集团股份有限公司 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN111356695B (zh) 2017-10-27 2022-12-30 北京加科思新药研发有限公司 新的三环化合物
CN115109061A (zh) * 2018-06-25 2022-09-27 北京加科思新药研发有限公司 三环化合物
CN113544129A (zh) 2019-04-04 2021-10-22 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用

Also Published As

Publication number Publication date
AU2019295983A1 (en) 2021-02-11
JP2021530455A (ja) 2021-11-11
AU2021290208A1 (en) 2022-01-20
TWI705965B (zh) 2020-10-01
AU2019295983B2 (en) 2021-09-30
ZA202100237B (en) 2022-10-26
CA3104927C (en) 2023-09-12
CN112513041A (zh) 2021-03-16
MX2020014111A (es) 2021-06-15
CN112513041B (zh) 2022-05-10
US11466005B2 (en) 2022-10-11
CN115109061A (zh) 2022-09-27
KR20210045981A (ko) 2021-04-27
EP3814352A1 (en) 2021-05-05
US20210179617A1 (en) 2021-06-17
JP7168245B2 (ja) 2022-11-09
US20220119390A1 (en) 2022-04-21
KR102600391B1 (ko) 2023-11-10
AU2021290208B2 (en) 2023-09-21
TW202017928A (zh) 2020-05-16
SG11202012819YA (en) 2021-01-28
CA3104927A1 (en) 2020-01-02
WO2020001152A1 (en) 2020-01-02
PH12020552210A1 (en) 2021-06-28
EP3814352A4 (en) 2022-03-30
BR112020026337A2 (pt) 2021-03-30

Similar Documents

Publication Publication Date Title
CR20210083A (es) Compuestos de anillo fusionado
PH12021551065A1 (en) Fused ring compounds
EA202092441A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201792229A1 (ru) Ингибиторы бромодомена
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA202190006A1 (ru) Пуриноновые соединения и их применение при лечении рака
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
EA202090497A1 (ru) Соединения и композиции для лечения гематологических нарушений
EA201790660A1 (ru) Ингибитор киназ
EA201690734A1 (ru) Ингибиторы бромодомена
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
CY1124762T1 (el) Αναστολεις πρωτεïνης δεσμευσης creb (cbp)
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190103A1 (ru) Трициклические соединения
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида
EA202190902A1 (ru) Ингибирование синтазы жирных кислот (fasn)